Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study

Among the discussed risk factors for high-titre inhibitor (HRI) development in patients with hemophilia A (HA) are high dose FVIII replacement therapy and use of recombinant FVIII concentrates (rFVIII). The aim of this study was to evaluate the aforementioned risk factors for HRI development in chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Halimeh, Susan, Bidlingmaier, Christoph, Heller, Christine, Gutsche, Sven, Holzhauer, Susanne, Kenet, Gili, Kurnik, Karin, Manner, Daniela, Iorio, Alfonso, Nowak-Göttl, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807559/
https://www.ncbi.nlm.nih.gov/pubmed/24199202
http://dx.doi.org/10.1155/2013/901975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807559/
https://www.ncbi.nlm.nih.gov/pubmed/24199202
http://dx.doi.org/10.1155/2013/901975

Ejemplares similares